

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: July 7, 2016	
Re.: Press Release.	


Dear Sir / Madam,

We enclose herewith a copy of press release dated July 7, 2016, titled “**Zydus enters into a sub-licensing agreement with The Medicines Patent Pool for Hepatitis C Medicine, daclatasvir.**” The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,
For, **Cadila Healthcare Limited**


Upen H. Shah
Company Secretary



Encl.: As above.

Zy+us enters into a sub-licensing agreement with The Medicines Patent Pool for Hepatitis C Medicine, daclatasvir

Zy+us to aid access to curative direct-acting antiviral in 112 low and middle-income countries

Ahmedabad, India, 7 July 2016

Zy+us Cadila, a leading global healthcare provider has signed a non-exclusive, royalty free agreement with The Medicines Patent Pool (MPP) for the generic production of Bristol-Myers Squibb's daclatasvir, a novel direct-acting antiviral (DAA) that is proven to help cure multiple genotypes of the Hepatitis C Virus (HCV). The agreement sub-licences Zy+us to produce and sell daclatasvir in 112 low and middle income countries.

Between 130 and 150 million people worldwide are estimated to have HCV. The vast majority lives in low and middle income countries. The MPP licence allows generic manufacturers to develop fixed-dose combinations that offer the potential to treat all of the six major genotypes of HCV. Daclatasvir, in combination with other DAAs, for example sofosbuvir, produces high cure rates after 12 weeks of treatment, with recent Phase III studies demonstrating that the regimen could cure up to 100% of HCV patients depending on genotype and stage of liver disease.

Speaking on the development, Chairman and Managing Director of the Zy+us group, Mr. Pankaj R. Patel said, "We are committed to delivering better therapy outcomes and improving the quality of life of people. We are happy to work together with The Medicines Patent Pool and Bristol-Myers Squibb to serve the cause of healthcare by providing access to new and affordable therapies to the economically disadvantaged communities across the developing countries."

Zy+us Heptiza, a specialty division of the group, has a complete basket of brands for hepatitis B & C with a reach of nearly 80% of the Hepatologists and Gastroenterologists across India. The addition of daclatasvir shall strengthen this critical care portfolio which offers the advantages of quality, globally accessed, preferred treatment options at affordable prices.

About Zy+us Cadila

Zy+us Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group launched its own patented NCE – Lipaglyn, the world's first drug to be approved for the treatment of diabetic dyslipidemia. It also launched 'Exemptia' the world's first biosimilar of Adalimumab for the treatment of inflammatory arthritis, Ulcerative Colitis and Crohn's Disease in adult & paediatric patients. The group aspires to be a research-based pharmaceutical company by 2020. The group employs over 19000 people worldwide and is dedicated to creating healthier communities globally.